A Phase 2, Open-Label Study of Amuvatinib in Combination With Platinum-Etoposide Chemotherapy in Small Cell Lung Cancer
Condition: Small Cell Lung Carcinoma · Sponsor: Astex Pharmaceuticals, Inc.
About this study
The purpose of the study is to evaluate the safety and potential benefit of combination amuvatinib with standard of care chemotherapy treatment (platinum and etoposide) in small cell lung cancer (SCLC) subjects.
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (12)
| University of Colorado Cancer Center | Aurora, Colorado, United States | — |
| Winship Cancer Institute of Emory University | Atlanta, Georgia, United States | — |
| James Graham Brown Cancer Center, University of Louisville | Louisville, Kentucky, United States | — |
| Washington University School of Medicine | St Louis, Missouri, United States | — |
| Associates in Oncology and Hematology | Chattanooga, Tennessee, United States | — |
| Vanderbilt - Ingram Cancer Center | Nashville, Tennessee, United States | — |
| MD Anderson Cancer Center | Houston, Texas, United States | — |
| Wojewódzki Szpital Specjalistyczny | Radom, Masovian Voivodeship, Poland | — |
| Centrum Onkologii - Instytut im. M. Sklodowskiej-Curie w Warszawie | Warsaw, Masovian Voivodeship, Poland | — |
| Wojewódzki Szpital im. Św. Ojca Pio w Przemyślu Oddział Onkologiczny z Pododdziałem Dziennej Chemioterapii | Przemyśl, Podkarpackie Voivodeship, Poland | — |
| Wojewódzkie Centrum Onkologii | Gdansk, Pomeranian Voivodeship, Poland | — |
| Specjalistyczny Szpital im. Alfreda Sokolowskiego | Szczecin, West Pomeranian Voivodeship, Poland | — |
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT01357395